Pfizer proposes to expand vaccine trial against advanced coronavirus

0
30


Pfizer’s global headquarters are located in Midtown Manhattan, New York.Drew Angerer | Getty Images

Pfizer and German biotech company BioNTech announced on Saturday that they have submitted a proposal to the United States Food and Drug Administration to expand the phase three trial of its coronavirus vaccine to 44,000 participants, a significant increase from its previous goal of 30,000.The companies, which are developing the vaccine together, said in a statement that the trial is proceeding as planned and that they expect to have recruited 30,000 participants by next week.

–CNBC Meg Tirrell contributed to this report.

LEAVE A REPLY

Please enter your comment!
Please enter your name here